Pharma stocks in good health; Divi’s Labs, Lupin jump up to 3%

NEW DELHI: Gains in shares of Divi’s Laboratories (up 2.94 per cent), Lupin (up 2.30 per cent) and Cadila Healthcare (up 1.79 per cent) lifted Nifty Pharma index up in morning trade on Thursday.

Lupin’s US arm is recalling 11,706 bottles of Lisinopril tablets, used for treating hypertension, from the American market, USFDA said. The product being recalled by Lupin Pharmaceuticals Inc is in the strength of 10mg, the US health regulator said in an Enforcement Report.

The Nifty Pharma index was trading 0.97 per cent up at 10,047 around 10:30 am.

Dr. Reddy’s Laboratories (up 1.74 per cent), Cipla (up 1.71 per cent) and Aurobindo Pharma (up 1.66 per cent) too were trading with gains.

However, Piramal Enterprises (down 0.96 per cent) and Glenmark Pharmaceuticals (down 0.30 per cent) were trading in the red, whereas shares of Sun Pharmaceutical Industries (up 0.09 per cent) and Biocon (up 0.01 per cent) were almost flat around that time.

Market came down from record highs on selling in bank, metal and auto stocks.

Benchmark NSE Nifty50 index was down 9 points at 11,561, while the BSE Sensex was 7 points down at 38,279.25.

Among the 50 stocks in the Nifty index, 25 were trading in the green, while 25 were in the red.

HDFC, Hindustan Unilever and Reliance Industries were trading up in the Nifty index.

  • Related Posts

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by week 1 and sustained through study end, alongside low rates of…

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    After substandard drug manufacturing, the state drug firms are once again under the scanner of the central government for manufacture and sale of unapproved fixed dose combination (FDC) drugs which…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise